Search the Newsreel

Processa Pharmaceuticals shareholders approve incentive plan amendment and board elections

Processa Pharmaceuticals (NASDAQ:PCSA) shareholders approved several key proposals at their 2026 Annual Meeting. These included amending the 2019 Omnibus Incentive Plan to increase shares available for issuance by 200,000, electing six director nominees, and ratifying Cherry Bekaert, LLP as the independent registered public accounting …

Form 8K Processa Pharmaceuticals Inc For: 11 August By Investing.com

This article reports that Processa Pharmaceuticals Inc. filed a Form 8K on August 11, 2026. The filing is a standard disclosure document required by the SEC for significant events that shareholders should know about. No specific details about the content of the 8K are …

Processa Pharmaceuticals Inc (PCSA) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Processa Pharmaceuticals Inc (PCSA), noting that no earnings forecast score is currently available. It details the average price target from analysts, which is $1.00, suggesting a significant upside. The report also includes recent and expected EPS figures …

Processa Pharmaceuticals Inc (NASDAQ: PCSA) Share Price, PCSA Stock News, PCSA Share Price & Updates

Processa Pharmaceuticals Inc (PCSA) Stock News Today

Processa Pharmaceuticals held annual shareholder meeting, quorum met by proxy or in person

Processa Pharmaceuticals held its 2026 annual shareholder meeting on July 30, 2026. Shareholders approved an amended 2019 omnibus incentive plan, ratified Cherry Bekaert as the independent accounting firm for 2026, and approved a slate of six directors. This news brief was generated by AI …

Processa Pharmaceuticals (NASDAQ: PCSA) adds 200,000 incentive shares

Processa Pharmaceuticals (NASDAQ: PCSA) announced that its shareholders approved an amendment to the company’s 2019 Omnibus Incentive Plan during its 2026 Annual Meeting. This amendment increases the number of shares available for issuance under the plan by 200,000. The proposal received significant shareholder support, …

Mintz Advises on $200 Million Private Placement Concurrent with Vidya Therapeutics’ and Processa Pharmaceuticals’ Merger Transaction

Mintz advised the placement agents on a $200 million private placement, which was executed in conjunction with Processa Pharmaceuticals, Inc.'s acquisition of Vidya Therapeutics, Inc. Leerink Partners led the placement, with Evercore ISI, UBS Investment Bank, and Wells Fargo Securities acting as co-placement agents. …

Processa Pharmaceuticals (PCSA) M&A announcement Summary

Processa Pharmaceuticals (PCSA) announced an M&A deal involving the acquisition of Vidya, bringing a new CNS-penetrant BTK inhibitor (VT-7208) into its pipeline to target immune-mediated and neuroinflammatory diseases. The transaction is structured as a stock-for-stock exchange, coupled with a $200 million private placement that …

Processa Pharmaceuticals Inc

Processa Pharmaceuticals announced its acquisition of Vidya Therapeutics through an all-stock deal. This acquisition grants Processa access to Vidya's lead drug candidate, which is designed to target immune system-related diseases. Additionally, Processa Pharmaceuticals raised $200 million to fund upcoming drug trials.

Processa Pharmaceuticals (NASDAQ: PCSA) director awarded Series A preferred in Vidya merger

Processa Pharmaceuticals director Sheila Gujrathi acquired Series A Non-Voting Convertible Preferred Stock on July 28, 2026, as part of the company's merger with Vidya Therapeutics, Inc. Gujrathi directly received over 70,000 Series A Preferred shares and indirectly holds an additional 12,311 shares through SilverArc …

Processa acquires CNS-penetrant BTK inhibitor VT-7208 with USD 200m financing for three Phase II programs

Processa Pharmaceuticals has acquired Vidya Therapeutics, gaining the CNS-penetrant BTK inhibitor VT-7208. The acquisition, a stock-for-stock transaction, is supported by a $200 million private placement, enabling Processa to fund three parallel Phase II clinical programs for food allergy, chronic spontaneous urticaria, and relapsing multiple …

PROCESSA PHARMACEUTICALS, INC. ANNOUNCES ACQUISITION OF VIDYA THERAPEUTICS, INC. AND APPROXIMATELY $200 MILLION CONCURRENT PRIVATE PLACEMENT TO ADVANCE BTK INHIBITOR, VT-7208, IN MULTIPLE DISEASE AREA

Processa Pharmaceuticals, Inc. has announced the acquisition of Vidya Therapeutics, Inc., a clinical-stage biotechnology company. This acquisition, coupled with an approximately $200 million private placement, aims to advance Vidya's lead asset, VT-7208, a BTK inhibitor, into Phase 2 proof-of-concept studies for food allergy, chronic …

PCSA Stock Jumps As Traders Zero In On Volatile Runway

Processa Pharmaceuticals Inc. (PCSA) stock experienced a significant jump in recent days, attracting speculative interest and momentum traders despite underlying financial weaknesses. The company faces heavy losses and negative cash flow, indicating potential dilution risk through future stock offerings. Traders are closely watching key …

Processa buys Vidya Therapeutics, raises $200 million for drug trials

Processa Pharmaceuticals announced it acquired Vidya Therapeutics in an all-stock deal, gaining access to a lead candidate for immune system diseases. Concurrently, Processa raised $200 million through a share sale to fund the development of VT-7208, an experimental drug for allergies, skin conditions, and …

Processa Pharmaceuticals Acquires Vidya Therapeutics, Secures $200 Million to Advance BTK Pipeline

Processa Pharmaceuticals has acquired Vidya Therapeutics and secured a $200 million private placement to create a recapitalized immunology and neurology company. This move will advance Vidya's lead asset, VT-7208, a BTK inhibitor, into parallel Phase 2 studies for food allergy, chronic spontaneous urticaria, and …

Processa Merges With Vidya and Secures $200 Million PIPE; Terminates Elion License

Processa Pharmaceuticals (PCSA) has completed its merger with Vidya Therapeutics, issuing shares to Vidya holders and targeting a tax-free reorganization. The company also secured a $200 million PIPE (Private Investment in Public Equity) of Series A preferred stock, expected to close on July 30, …

Processa adds BTK therapy programs for food allergy and multiple sclerosis

Processa Pharmaceuticals (PCSA) has acquired Vidya Therapeutics, gaining its lead asset VT-7208, a BTK inhibitor for food allergy, chronic spontaneous urticaria (CSU), and relapsing multiple sclerosis (RMS). Concurrently, Processa secured an approximately $200 million private placement, providing a cash runway into the second half …

Form 4 Processa Pharmaceuticals Inc For: 28 July By Investing.com

This article from Investing.com announces a Form 4 filing for Processa Pharmaceuticals Inc. dated July 28. It provides no further details on the content of the filing but lists the company's stock symbol and current performance. The brief article is embedded within a larger …

Processa Pharmaceuticals (PCSA) awards 8,450 RSUs and reports option, stock holdings

Processa Pharmaceuticals, Inc. (PCSA) executive Patrick Lin was granted 8,450 Restricted Stock Units (RSUs) on July 26, 2026. These RSUs vest immediately but will be distributed upon termination, six months post-grant, change of control, or death. Following this award, Lin holds 11,389 RSUs, stock …

Processa Pharmaceuticals, Inc. (PCSA) CEO receives 9,384 RSUs grant

Processa Pharmaceuticals, Inc. CEO George K. Ng was granted 9,384 Restricted Stock Units (RSUs) on July 26, 2026. These RSUs represent a contingent right to receive one common share each, vesting immediately but with deferred settlement until specific conditions are met. Following this award, …

Processa Pharmaceuticals (NASDAQ: PCSA) grants director 33,500 RSUs and options

Processa Pharmaceuticals director Justin W. Yorke received a grant of 33,500 Restricted Stock Units (RSUs) on July 26, 2026. These RSUs vested immediately but distribution is deferred until specific events like termination, six months post-grant, change of control, or death. Following this transaction, his …

Processa Pharmaceuticals Inc (PCSA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Processa Pharmaceuticals Inc (PCSA), highlighting its current risk score and ranking within the Biotechnology & Medical Research industry. It details key metrics such as beta value, maximum drawdown, volatility, and various return metrics over different periods. The …

Processa Pharmaceuticals Inc (PCSA) Earnings Date & Reports & Earnings News

PCSA|Processa Pharmaceuticals Inc|Price:2.605|Chg%:+0.005

Processa Pharmaceuticals Inc. (PCSA) is a clinical-stage biopharmaceutical company focused on Next Generation Cancer therapy (NGC) small molecules. The company's stock is currently trading at $2.565, with recent positive performance over the last month and a high institutional ownership. While fundamentals are strong and …

Processa Pharmaceuticals Inc (PCSA) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Processa Pharmaceuticals Inc (PCSA), detailing its price momentum, support and resistance levels, and various technical indicators. As of July 24, 2026, PCSA's stock price is trading between 1.88 (support) and 3.10 (resistance), with a current price momentum …

Processa Pharmaceuticals Inc (PCSA) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Processa Pharmaceuticals Inc (PCSA), giving it a current financial score of 7.06, ranking it 155 out of 386 in the Biotechnology & Medical Research industry. The company's financial status is described as robust, although its operating efficiency …

Processa Pharmaceuticals Inc (PCSA) Valuation: PE, PB & Fair Value Analysis

Processa Pharmaceuticals Inc (PCSA) currently has a valuation score of 7.01, placing it 276th out of 386 in the Biotechnology & Medical Research industry. The company's P/E ratio is -0.62, which is significantly below its recent high and above its recent low. Key valuation …